Eddie Cliff (@eddie_cliff) 's Twitter Profile
Eddie Cliff

@eddie_cliff

haematology registrar | ex-@harvardmed @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | co-host @BloodCancerTalk

ID: 74081884

linkhttp://edwardcliff.com calendar_today14-09-2009 05:25:57

13,13K Tweet

4,4K Followers

2,2K Following

Raj Chakraborty (@rajshekharucms) 's Twitter Profile Photo

A short🧵on FISH in AL #Amyloidosis and findings of our multicenter study on 283 patients with AL treated with daratumumab-based frontline therapy (Dara-VCd/Dara-Vd) Blood Journal ashpublications.org/blood/article-…

Samer Al Hadidi, MD,MS,FACP (@hadidisamer) 's Twitter Profile Photo

Evaluating early intervention in smoldering myeloma clinical trials: a systematic review The Oncologist #mmsm ➡️academic.oup.com/oncolo/article… Responses to similar treatments are usually lower in smoldering myeloma compared to multiple myeloma👇

Evaluating early intervention in smoldering myeloma clinical trials: a systematic review <a href="/OncJournal/">The Oncologist</a> #mmsm 

➡️academic.oup.com/oncolo/article…

Responses to similar treatments are usually lower in smoldering myeloma compared to multiple myeloma👇
The Oncologist (@oncjournal) 's Twitter Profile Photo

This article reviews clinical trials of smoldering multiple myeloma, comparing efficacy of treatment regimens in smoldering multiple myeloma to results from these regimens when used in newly diagnosed multiple myeloma. doi.org/10.1093/oncolo… #myeloma #BloodCancerAwareness

This article reviews clinical trials of smoldering multiple myeloma, comparing efficacy of treatment regimens in smoldering multiple myeloma  to results from these regimens when used in newly diagnosed multiple myeloma.
doi.org/10.1093/oncolo…
#myeloma #BloodCancerAwareness
The EBMT (@theebmt) 's Twitter Profile Photo

📣 Major milestone reached: 10,000 CAR-T treated #patients registered in the #EBMT Registry! 🙌 📈 This achievement highlights the incredible progress and growing impact of chimeric antigen receptor T-cell (CAR-T) therapy in treating haematological malignancies. 🔬 We are very

📣 Major milestone reached: 10,000 CAR-T treated #patients registered in the #EBMT Registry! 🙌

📈 This achievement highlights the incredible progress and growing impact of chimeric antigen receptor T-cell (CAR-T) therapy in treating haematological malignancies. 🔬 We are very
Robert Z. Orlowski (@myeloma_doc) 's Twitter Profile Photo

#Myeloma Paper of the Day: Systematic review & meta-analysis of 5,517 lymphoma & myeloma patients post-CAR T finds overall SPM point estimate of 5.8%, but no differences in randomized studies vs. control arms (p=0.92): pubmed.ncbi.nlm.nih.gov/39256908/. #mmsm

#Myeloma Paper of the Day: Systematic review &amp; meta-analysis of 5,517 lymphoma &amp; myeloma patients post-CAR T finds overall SPM point estimate of 5.8%, but no differences in randomized studies vs. control arms (p=0.92): pubmed.ncbi.nlm.nih.gov/39256908/. #mmsm
Eddie Cliff (@eddie_cliff) 's Twitter Profile Photo

Will be interesting to see which recommendations the government chooses to implement and how quickly Good to see emphasis on trying to increase access & speed of access Mark Butler MP Dr Monique Ryan MP

Penn LDI (@pennldi) 's Twitter Profile Photo

How are public and private insurers thinking about paying for new cell & gene therapies? This Friday, our expert panel will unpack the current landscape and options for increasing access to these treatments while creating sustainable payment strategies. ldi.upenn.edu/events/coverin…

Kai Rejeski (@krejeski) 's Twitter Profile Photo

Excited to share our new paper focusing on Second Primary Malignancies (SPMs) following CAR T-cell therapy out today in Clinical Cancer Research ! 👇 This first-in-kind meta-analysis spans 5,517 lymphoma and myeloma patients receiving a range of CAR-T products. aacrjournals.org/clincancerres/…

Bruce Levine, Ph.D. 🇺🇦 (@bllphd) 's Twitter Profile Photo

Mega CAR T meta-analysis "Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients" Bottom line: - frequency of SPMs w CAR-T is not increased compared to SOC strategies -SPM occurrence after CAR T is

Mega CAR T meta-analysis "Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients" Bottom line: 
- frequency of SPMs w CAR-T is not increased compared to SOC strategies
-SPM occurrence after CAR T is
Michael Jain (@michaeldjain) 's Twitter Profile Photo

Great talk by Dr. Falchi (MSK) at the T cell immunotherapy meeting in Bologna - starting to unravel resistance mechanisms to bispecific antibodies and designing trials to address them medrxiv.org/content/10.110…

Eddie Cliff (@eddie_cliff) 's Twitter Profile Photo

AutoSCT vs alloSCT in CR1 for PTCL Long term f/up of AATT RCT Journal of Clinical Oncology 7 yr EFS: allo 38% v auto 34% 7 yr OS: allo 55% v auto 61% 15/30 pts w early PD, 11/20 pts w post-auto PD had allo. 7 yr OS post salvage allo 61%, NRM 23% ascopubs.org/doi/10.1200/JC… Allo the goal in fit PTCL

AutoSCT vs alloSCT in CR1 for PTCL
Long term f/up of AATT RCT <a href="/JCO_ASCO/">Journal of Clinical Oncology</a>

7 yr EFS: allo 38% v auto 34%
7 yr OS: allo 55% v auto 61%

15/30 pts w early PD, 11/20 pts w post-auto PD had allo. 7 yr OS post salvage allo 61%, NRM 23%

ascopubs.org/doi/10.1200/JC…

Allo the goal in fit PTCL
Carlos Alvarez (@duemed) 's Twitter Profile Photo

Can anyone explain why we continue to see RCTs in mCRPC with ARPI-switch as the control arm? How is the discussion with the patient when offering to participate in trials with this comparator?

Steven Tong (@syctong) 's Twitter Profile Photo

This is well worth a read, I've done so twice so far, if interested in Bayesian statistics for research and clinical trials. Very clearly written. thelancet.com/journals/lance…